Compare BC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | SRRK |
|---|---|---|
| Founded | 1845 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.6B |
| IPO Year | N/A | 2018 |
| Metric | BC | SRRK |
|---|---|---|
| Price | $79.12 | $46.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $77.67 | $56.17 |
| AVG Volume (30 Days) | 766.7K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.81 | N/A |
| Revenue Next Year | $5.11 | $534.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.40 | $27.07 |
| 52 Week High | $90.25 | $51.63 |
| Indicator | BC | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 46.05 |
| Support Level | $78.15 | $45.59 |
| Resistance Level | $89.67 | $47.96 |
| Average True Range (ATR) | 2.88 | 1.71 |
| MACD | 0.49 | -0.42 |
| Stochastic Oscillator | 57.69 | 4.25 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns 442 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.